Göðüs Hastanesi Dergisi. 2020; 34(3): 118-123 | DOI: 10.5222/IGH.2020.68077

Rituksimab Ýliþkili Ýnterstisyel Akciðer Hastalýðý

Rabýa Hande Avcý, Ecem Naz Ertürk, Mukadder Calikoglu, Eylem Sercan Ozgur
Mersin Üniversitesi Týp Fakültesi, Göðüs Hastalýklarý Ana Bilim Dalý, Mersin

Rituksimab günümüzde kullanýmý giderek artan, lenfoma, kronik lenfositik lösemi, romatoid
artrit, transvers myelit gibi hastalýklarýn tedavisinde kullanýlan, interstisyel akciðer hastalýðýna
sebep olabilen CD 20 antijenine karþý geliþtirilen monoklonal bir antikordur. Transvers myelit
nedeni ile rituksimab tedavisi alan 59 yaþýnda kadýn hasta ilaç kullanýmýndan sonra acil servise
nefes darlýðý, öksürük, ateþ þikayeti ile baþvurdu. Klinik ve radyolojik deðerlendirmeler sonucunda
hastaya ilaca baðlý interstisyel akciðer hastalýðý tanýsý kondu. Rituksimab tedavisinin sonlandýrýlmasý
ve metilprednizolon baþlanmasýndan bir ay sonra hastanýn klinik ve radyolojik bulgularýnda
düzelme saðlandý. Sonuç olarak interstisyel akciðer hastalýðýnda primer neden araþtýrýlýrken
hastanýn kullandýðý ilaçlar bu açýdan sorgulanmalý ve rituksimab gibi diðer birçok ilacýn etyolojide
yer alabileceði akýlda tutulmalýdýr.

Anahtar Kelimeler: Ýnterstisyel Akciðer Hastalýðý, Rituksimab, Transvers Myelit

---

Rituksimab-Related Interstitial Lung Disease

Rabýa Hande Avcý, Ecem Naz Ertürk, Mukadder Calikoglu, Eylem Sercan Ozgur
Department Of Chest Diseases, Mersin University Faculty Of Medicine, Mersin, Turkey

Rituximab is a monoclonal antibody which is developed against CD 20 antigen, increasingly
used nowadays. While it is used in the treament of the diseases such as lymphoma, chronic
lymphocytic leukemia, rheumatoid arthritis, transverse myelitis; can also cause interstitial lung
disease. A 59 year old female patient who has been followed up with the disease of transverse
myelitis and receiving rituximab therapy, applied to the emergency department with labored
breath, cough, and fever after drug use. As a result of clinical and radiological evaluations, the
patient has diagnosed as drug-related interstitial lung disease. One month after the termination
of rituximab therapy and the start of methylprednisolone, the patient’s clinical and radiological
findings improved. In conclusion, while investigating the primary cause in interstitial lung disease,
the drugs used by the patient should be questioned in this respect and it should be kept in
mind that many other drugs such as rituximab can be involved in the etiology.

Keywords: Interstitial Lung Disease, Rituximab, Transverse Myelitis

---

ATIF KOPYALA